Shares of other companies:
May 11, 2024 AppLovin Joins Elite 100% Return Club!
Apple: Here’s My Price Target And WWDC Strategy
May 17, 2024
Tesla Is Selling More Than Cars With FSD
May 17, 2024
Nvidia Faces Macro Headwinds And Micro Tailwinds
May 15, 2024
April 23, 2024 Maximizing Profits: When is the Right Time to Sell Your Business?
Selling a business can be a momentous decision filled with many considerations and uncertainties. As an entrepreneur, this also symbolizes your years of…
April 12, 2024 Improve Your Financial Status: A How-To Guide
Navigating through the complexities of personal finance can often feel like walking through a maze blindfolded. This guide is crafted especially for you,…
April 12, 2024 How ZIM Integrated Container Tracking is Revolutionizing Global Trade
Have you ever wondered how your online shopping packages get to you? A big part of the answer is ZIM Integrated Container Tracking.…
March 15, 2024 6 Best Growth Stocks To Buy Now According to Metatrader 5
One of the reasons investors prefer growth stocks is that they are expected to perform better than other companies in terms of sales…
AFMD Stock News and Mentions of Affimed N.V. Stocktwits
Updated: May 18, 2024 (09:13)
Sector: Healthcare
Welcome to PandaPulse, innovative analytical stock market observer, where the latest news and stocktwits meets in-depth investor relations insights. Dive into our real-time sentiment analysis to gauge the mood of the markets and arm yourself with key information that resonates with both savvy investors and casual traders.
We meticulously analyze the sentiment trend in each article for the last 60 days where Affimed N.V. Company is mentioned. We assess its relevance and importance to carry out an overall sentiment valuation of Affimed N.V. (AFMD).
You can view the trend designation for each individual article below. We use this data to compile indicators into one comprehensive sentiment value, which represents the current information agenda about the Affimed N.V. stocks.
Please wait, while the data is preparing...
General evaluation of the current information agenda's sentiments
Agenda Trend
Analyzed articles
News and Mentions of Affimed N.V. (AFMD)
May 14, 2024 (14:05) / "GlobeNewswire" (by Affimed N.V.)
Affimed Announces Acceptance of an Abstract on Preclinical Data of its Innate Cell Engager AFM28 at the European Hematology Association 2024 Congress
MANNHEIM, Germany, May 14, 2024 ( GLOBE NEWSWIRE ) -- Affimed N.V. ( Nasdaq: AFMD ) , a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced the publication of an abstract for the annual congress of the European Hematology ...
In Article Trend: Neutral
May 14, 2024 (12:15) / "Zacks Commentary" (by Zacks Equity Research)
Immatics ( IMTX ) Reports Q1 Loss, Tops Revenue Estimates
Immatics (IMTX) delivered earnings and revenue surprises of 94.59% and 85.05%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
In Article Trend: Neutral
May 10, 2024 (00:00) / "Zacks Commentary" (by Zacks Equity Research)
Xenetic Biosciences ( XBIO ) Reports Q1 Loss, Misses Revenue Estimates
Xenetic Biosciences (XBIO) delivered earnings and revenue surprises of 1.27% and 21.39%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
In Article Trend: Neutral
April 30, 2024 (15:55) / "Zacks Commentary" (by Zacks Equity Research)
Analyzing How You Should Play Cigna ( CI ) Ahead of Q1 Earnings
The first-quarter results of Cigna (CI) are likely to reflect expanding commercial middle market memberships and growth in Cigna Healthcare profits.
In Article Trend: Bullish
April 24, 2024 (13:55) / "Zacks Commentary" (by Zacks Equity Research)
Wall Street Analysts Believe Affimed N.V. ( AFMD ) Could Rally 146.73%: Here's is How to Trade
The consensus price target hints at a 146.7% upside potential for Affimed N.V. (AFMD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
In Article Trend: Somewhat-Bullish
April 24, 2024 (08:05) / "GlobeNewswire" (by Affimed N.V.)
Affimed Announces Acceptance of AFM24 Clinical Abstract at the 2024 Annual Meeting of the American Society of Clinical Oncology
MANNHEIM, Germany, April 24, 2024 ( GLOBE NEWSWIRE ) -- Affimed N.V. ( Nasdaq: AFMD ) , a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced that an abstract presenting preliminary data from the phase 2 combination study ...
In Article Trend: Neutral
April 17, 2024 (13:55) / "Zacks Commentary" (by Zacks Equity Research)
Affimed N.V. ( AFMD ) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
After losing some value lately, a hammer chart pattern has been formed for Affimed N.V. (AFMD), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
In Article Trend: Somewhat-Bullish
April 4, 2024 (13:55) / "Zacks Commentary" (by Zacks Equity Research)
Does Affimed N.V. ( AFMD ) Have the Potential to Rally 263.36% as Wall Street Analysts Expect?
The consensus price target hints at a 263.4% upside potential for Affimed N.V. (AFMD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
In Article Trend: Somewhat-Bullish
March 28, 2024 (10:30) / "GlobeNewswire" (by Affimed N.V.)
Affimed Reports 2023 Financial Results and Operational Progress
MANNHEIM, Germany, March 28, 2024 ( GLOBE NEWSWIRE ) -- Affimed N.V. ( Nasdaq: AFMD ) ( "Affimed" or the "Company" ) , a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today reported financial results and provided an update on ...
In Article Trend: Neutral
March 21, 2024 (10:30) / "GlobeNewswire" (by Affimed N.V.)
Affimed To Report Full Year 2023 Financial Results & Corporate Update on March 28, 2024
MANNHEIM, Germany, March 21, 2024 ( GLOBE NEWSWIRE ) -- Affimed N.V. ( Nasdaq: AFMD ) ( "Affimed" or the "Company" ) , a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it will release full year 2023 results and ...
In Article Trend: Neutral
Related stocks from Healthcare sector
This website uses cookies to ensure you get the best experience on our website